Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Clinical Study of Dose Escalation and Dose Expansion of SHR-1501 Alone or in Combination With Bacille de Calmette Guerin （BCG） or SHR-1316 in the Treatment of Non-muscle Invasive Bladder Cancer（NMIBC）

NCT05410730 is registered in ClinicalTrials.gov with Shanghai Hengrui Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05410730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05410730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Clinical Study of Dose Escalation and Dose Expansion of SHR-1501 Alone or in Combination With Bacille de Calmette Guerin （BCG） or SHR-1316 in the Treatment of Non-muscle Invasive Bladder Cancer（NMIBC）
Lead sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 23, 2022
Completion date
May 31, 2027
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high-risk nmibc